Lung cancer EGFR mutations tend to occur in the kinase domain, whereas GBM EGFR mutations are mainly in the extracellular domain, which could allow the GBM mutant receptors sufficient flexibility within the kinase domain to accommodate lapatinib and other type II EGFR kinase inhibitors (93). Here, EGFR is linked to lung carcinoma.